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Abstract
Background. Integration of biomarker data with information on health and lifestyle provides
a powerful tool to enhance the scientific value of health research. Existing health and demo-
graphic surveillance systems (HDSSs) present an opportunity to create novel biodata resources
for this purpose, but data and biological sample collection often presents challenges. We out-
line some of the challenges in developing these resources and present the outcomes of a bio-
marker feasibility study embedded within the South East Asia Community Observatory
(SEACO) HDSS.
Methods.We assessed study-related records to determine the pace of data collection, response
from potential participants, and feedback following data and sample collection. Overall and
stratified measures of data and sample availability were summarised. Crude prevalence of
key risk factors was examined.
Results. Approximately half (49.5%) of invited individuals consented to participate in this
study, for a final sample size of 203 (161 adults and 42 children). Women were more likely
to consent to participate compared with men, whereas children, young adults and individuals
of Malay ethnicity were less likely to consent compared with older individuals or those of any
other ethnicity. At least one biological sample (blood from all participants – finger-prick and
venous [for serum, plasma and whole blood samples], hair or urine for adults only) was
successfully collected from all participants, with blood test data available from over 90% of
individuals. Among adults, urine samples were most commonly collected (97.5%), followed
by any blood samples (91.9%) and hair samples (83.2%). Cardiometabolic risk factor burden
was high (prevalence of elevated HbA1c among adults: 23.8%; of elevated triglycerides among
adults: 38.1%; of elevated total cholesterol among children: 19.5%).
Conclusions. In this study, we show that it is feasible to create biodata resources using existing
HDSS frameworks, and identify a potentially high burden of cardiometabolic risk factors that
requires further evaluation in this population.
Introduction
There is a need for comprehensive data resources on population health and disease in low- and
middle-income countries, where a large proportion of the global burden of morbidity and
mortality is located (1, 2). Biomarker data form an essential component of such endeavours,
allowing objective assessment of a wide range of disease-related indices, facilitating validation
of self-reported information, and allowing for greater statistical power of analyses. Integration
of biomarker data with information on health and lifestyle provides a powerful tool to enhance
the scientific value of health research.
Large-scale surveys in low- and middle-income populations, such as the Demographic and
Health Surveys, have previously included biomarker modules (3). However, these have often
been restricted to a narrow range of measures from limited samples, with variable capacity
for long-term storage and later analysis (3). Importantly, they are unable to follow up indivi-
duals over time. Health and demographic surveillance system (HDSS) sites offer a valuable
opportunity for efficient, large-scale collection and analysis of biomarker data. They provide
pre-existing infrastructure to facilitate biological sample collection, and the potential to link
biomarker data longitudinally to historical and future measures. This linkage allows for a
detailed view of disease development across the life course (4).
We undertook a biomarker feasibility study embedded within the South East Asia
Community Observatory (SEACO) HDSS, which covers approximately 45 000 individuals
in Segamat, Malaysia (5). The SEACO HDSS conducts annual enumeration of individuals,
and has also undertaken a population-wide health survey collecting questionnaire data and
biophysical measurements, in its catchment area (5). Through this study, we explored the
feasibility of building upon the previous survey work conducted
by SEACO to include biological sample collection. This feasibility
study aimed to recruit approximately 200 individuals aged seven
years and above to assess the preparedness of individuals and
families to participate, and to establish the procedures for the
collection, analysis and storage of biological samples within a
predominantly rural community setting. Here, we outline the
developments in the procedures and examine the outcomes of this
study to determine the potential to create a large-scale biodata
resource within the full HDSS population.
Methods
A detailed profile of the SEACO HDSS, including the HDSS
development, structure, and data collections, is presented in a
recent publication (5).
Sampling
Adult (aged 18 years and over) and child (aged 7–17 years) par-
ticipants for this study were recruited from the SEACO HDSS (5).
Stratified random sampling was performed at the household level
using data from the most recent enumeration (completed in
2016), aiming to achieve comparable proportions of individuals
of Malay, Indian, Chinese and Orang Asli (indigenous) ethnicity.
Sampling therefore covered all enumerated households within the
SEACO catchment area (approximately 1250 km2). SEACO has
established strong community links through its community
engagement strategy (6), and additional community awareness
activities were undertaken to sensitise potential participants
prior to this study.
Data and sample collection
Community-based data and sample collection was undertaken by
two field teams between November 2016 and February 2017. Data
were recorded on electronic tablets. Informed consent (adults) or
informed assent with parental or guardian consent (children) was
first obtained; individuals could only participate if they consented
to providing all data and samples (Supplementary Methods).
Following informed consent, along with questionnaire and bio-
physical data, capillary blood (via finger prick, for point-of-care
glycated haemoglobin [HbA1c] measurement), and venous
blood (four tubes from a single blood draw: up to 24 ml from
adults, 12 ml from children; for serum, plasma and whole blood
samples) were collected from participants. Hair and urine samples
were also collected from adult participants. Following data and
sample collection, participants were given their body mass
index (BMI), blood pressure and point-for-care HbA1c results,
and were provided referral to local clinics if these were above pre-
determined cut-offs. One session of data and sample collection
took approximately 40–50 minutes for adult participants and 30
minutes for children (see Supplementary Methods for further
details on sample collection purposes and procedures).
Measures and statistical analysis
Study measures to evaluate scale-up
Literature on suitable measures or assessment frameworks to
determine feasibility for population-based observational studies
is scarce (7–10). We therefore identified and examined a range
of study-related measures to gain a comprehensive picture of
the potential for scale-up. This included indicators of efficiency,
response from potential participants, feedback from participants,
and completeness and quality of collected data and samples.
First, we summarised study operational data to assess oper-
ational efficiency and response to the study. This assessment
included information on the number of days of data and sample
collection; the number and demographic characteristics of house-
holds and individuals approached; proportions consenting,
declining or absent; reasons for refusal among those declining
participation; and post-study feedback among participating
individuals. Study pace was calculated as the average number of
participants recruited per day. Differences in demographic char-
acteristics between consenting and non-consenting individuals
were assessed using Pearson’s chi squared tests or Fisher’s exact
tests (cell counts less than five).
Following this, we examined measures relating to quality and
completeness of data and samples. We were particularly interested
in measures relating to blood sample collection, availability of
blood test data and availability of blood sample aliquots, as indi-
cators of the success of sample collection, analysis and storage.
We extracted relevant information from three datasets generated
at the end of the study: (i) data recorded on the electronic ques-
tionnaire form, (ii) blood test results, and (iii) records of receipt,
processing and aliquoting of biological samples at the central
research laboratory. All three datasets were cleaned, merged and
checked for consistency. The completeness of questionnaire data
for each participant was assessed by examining a set of all ques-
tions and measurements collected from all participants. The num-
ber of participants with any questionnaire data, blood test data,
collected samples and samples for storage (plasma, serum,
whole blood and remnant cell aliquots, urine aliquots and hair
samples) was examined, and differences by sex, ethnicity and
obesity status were assessed. The number of participants with
complete data and samples was similarly examined.
Sociodemographic, lifestyle and risk factor data
Finally, sociodemographic characteristics of study participants
and crude prevalence of key lifestyle, biophysical and blood-based
risk factors in the population were examined; differences by sex
were assessed using Pearson’s chi squared or Fisher’s exact tests
(see Supplementary Methods for list of variables and correspond-
ing definitions).
All data management and analyses were performed using Stata
14 (Statacorp, Texas).
Ethical approvals
Ethical approval for the study was obtained from the Monash
University Human Research Ethics Committee (CF16/471–
2016000227), and approval for the receipt and analysis of linked
anonymised data at the University of Cambridge was obtained
from the University Human Biology Research Ethics Committee
(HBREC.2017.04) (Supplementary Methods).
Results
Study measures to evaluate scale-up
Measures of study recruitment and response
Overall, 203 participants (161 adults, 42 children) were recruited
into the biomarker feasibility study, close to half (49.5%) of those
responding to an invitation to participate (Figure 1, Table 1).
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A notable proportion of houses was empty upon approach, either
due to the household having moved away (n = 107; 11.7%), or
household members not being at home (n = 383; 42.0%)
(Figure 1). Recruitment and data and sample collection occurred
over 48 working days, with an overall study pace of 4.2 partici-
pants per day (Supplementary Figures S1–S2). Among house-
holds providing reasons for refusal to participate (63.5%), the
most common included disinterest (16.2%) or fear of needles
(24.3%) (Supplementary Table S1).
A greater proportion of women (56%) versus men, individuals
aged 50–59 years (70.1%) or 60 years and above (64.7%) versus
younger individuals, and those of Orang Asli ethnicity (64.9%
among adults, 70.5% among children) versus those of any other
ethnicity were available during recruitment (Table 1). Of those
available and subsequently invited, women (68.5%, P < 0.001)
were more likely to consent to participate compared with men,
whereas children (30.0%) and young adults (48.2%), and those
of Malay ethnicity (adults: 41.3%, P < 0.001, children: 19.0%,
P = 0.129) were less likely to consent, compared with older
individuals or those of any other ethnicity (Table 1).
Of 170 (83.7%) participants providing post-study feedback,
over 95% agreed with comments relating to a favourable ex-
perience, including comfort during questionnaire administration
(99.4%), interest in the study results (100.0%), and willingness
to encourage others to participate in the study (99.4%)
(Supplementary Table S2).
Completeness and quality of data and samples
We then examined the availability of data and samples collected
from participants. All participants had some available question-
naire information, with most having three or fewer missing vari-
ables (Table 2, Supplementary Tables S3-S4). At least one
biological sample (capillary blood, venous blood, hair or urine)
was collected at the anticipated quantity from all individuals
(Table 2, Supplementary Table S5). Over 90% of participants
had some blood test data, whilst approximately 70–80% had com-
plete data (Table 2), with no systematic differences in data and
sample availability by ethnicity (Supplementary Figures S3–S4).
Given the potential to obtain detailed biomarker information
from blood, the availability and quality of blood samples was of
particular interest in this study. A capillary (finger-prick) blood
sample was successfully collected from all participants, with suc-
cessful point-of-care HbA1c measurement in almost all (99.0%)
participants (Table 2). At least one venous blood sample of
any volume was collected from over 90% of both adult and
child participants, with 82.6% of adults and 95.2% of children
having all four blood samples collected at any volume (Table 3;
Supplementary Tables S6-S7). Notably, obese adults were less
likely to have blood samples successfully collected (at least one
blood sample at any volume: 100% among non-obese adults ver-
sus 79.5% among obese adults, P = 0.002) (Supplementary
Table S8). Almost all collected blood samples passed as acceptable
quality by the research laboratory, for processing, analysis and
storage (Table 3; Supplementary Tables S6-S7). At least one stor-
age aliquot was available from all collected and accepted blood
samples among children, and over 96.2% of samples among
adults (Supplementary Tables S9-S10).
Sociodemographic, lifestyle and risk factor data
In addition to a notable prevalence of lifestyle and biophysical risk
factors, we found a high burden of blood-based cardiometabolic
risk factors in this population. Close to one quarter of adults
(23.8%) had elevated HbA1c, while 8.2% had elevated total chol-
esterol, 15.0% had low HDL cholesterol, and 38.1% had elevated
triglycerides (Table 4). Risk factor prevalence was similarly high
among children: 19.5% had elevated total cholesterol, 14.6% had
low HDL cholesterol and 36.6% had elevated triglycerides
(Table 4).
Discussion
Detailed, objective measures provided by biomarker information
are fundamental to comprehensive data resources on population
health and disease. In this study, we show the feasibility of
biomarker collection within the context of the SEACO HDSS.
Approximately half of invited individuals consented to participate
in biological sample collection, with favourable participant
feedback. Biological samples were collected from all participants.
Outcome measures indicated that there was scope to increase
study pace, and a need to improve blood sample collection
from obese participants, both attainable through appropriate
modifications to study design and training. A high prevalence
of blood-based cardiometabolic risk factors was observed
among both adult and child participants. These results indicate
that creation of a large-scale biodata resource is both achievable
and valuable in this population, with potential relevance to
similar HDSS sites.
We demonstrate here that capitalising on existing HDSS fra-
meworks to undertake biomarker collection is an efficient way
to encourage community participation, and to enhance their
value as data resources. We undertook biological sample collec-
tion by building upon the strong existing infrastructure, data,
human and material resources, local knowledge and community
and administrative links established by the SEACO HDSS (5).
The proportion of consenting versus invited participants observed
in this study is comparable to or greater than other large-scale
biobank or biomarker collection studies based in high-income
countries (11, 12). Participants were willing to provide both capil-
lary and venous blood samples, with successful capillary blood
collection for all participating individuals. Blood test data and
storage aliquots were available for the majority of participants,
indicating the successful establishment of procedures from sample
collection to analysis and long-term storage. Data and sample col-
lection took under an hour, and participants providing feedback
Fig. 1. Proportion of individuals (N = 912) in visited houses (N = 289) who consented,
refused, were not at home or were unavailable. Unavailable: individuals from visited
houses who were found to have moved away (n = 107) or passed away since the most
recent enumeration (n = 12). Individual not at home: eligible individuals who were not
at home at the time of the visit.
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responded favourably to the study. The community engagement
strategy previously established by SEACO provided a mechanism
through which individuals could raise and address concerns they
had with participation in this study (6). Importantly, we have the
capacity to link information obtained in this study with measures
from both previous and future HDSS data collections, including
later clinical outcomes, which will facilitate the creation of richer
datasets that may be explored in future analyses.
Compared with the growing focus on feasibility studies for
randomised clinical trials (13–24), literature on operational
outcomes of observational feasibility studies remains scarce, and
restricted to a limited number of measures, such as the overall
proportion of invited individuals ultimately participating (7–10).
Few studies have directly assessed measures of sample collection
feasibility, with none identified here that specifically examined
blood sample collection (7, 25). Here, we identified useful indica-
tors relating to various aspects of study operation including sam-
ple collection, using these in the context of our study to obtain a
clearer understanding of the feasibility of scale-up. Systematic
assessment of such measures may be useful to researchers
Table 1. Summary of individuals living in houses visited by the study team.
Eligible
individuals
living in visited
houses1 (n, %)
Invited2 (n, % of
eligible individuals)
Consented (n, % of
invited)
Refused (n, % of
invited) P (consented versus refused)
Adults
N 516 270 (52.3) 161 (59.6) 109 (40.4)
Sex
Male 250 (48.4) 121 (48.4) 59 (48.8) 62 (51.2)
Female 266 (51.6) 149 (56.0) 102 (68.5) 47 (31.5) 0.001
Age category (years)
18–29 148 (28.7) 56 (37.8) 27 (48.2) 29 (51.8)
30–39 93 (18.0) 46 (49.5) 31 (67.4) 15 (32.6)
40–49 103 (20.0) 52 (50.5) 35 (67.3) 17 (32.7)
50–59 87 (16.9) 61 (70.1) 36 (59.0) 25 (41.0)
60+ 85 (16.5) 55 (64.7) 32 (58.2) 23 (41.8) 0.239
Ethnicity
Malay 191 (37.0) 104 (54.5) 43 (41.3) 61 (58.7)
Indian 145 (28.1) 57 (39.3) 41 (71.9) 16 (28.1)
Chinese 102 (19.8) 58 (56.9) 37 (63.8) 21 (36.2)
Bumiputera/Orang Asli 77 (14.9) 50 (64.9) 39 (78.0) 11 (22.0)
Other 1 (0.2) 1 (100.0) 1 (100.0) 0 (0.0) <0.001
Children
N 277 140 (50.5) 42 (30.0) 98 (70.0)
Sex
Male 142 (51.3) 73 (51.4) 23 (31.5) 50 (68.5)
Female 135 (48.7) 67 (49.6) 19 (28.4) 48 (71.6) 0.685
Age category (years)
7–12 161 (58.1) 77 (47.8) 17 (22.1) 60 (77.9)
13–17 116 (41.9) 63 (54.3) 25 (39.7) 38 (60.3) 0.024
Ethnicity
Malay 93 (33.6) 42 (45.2) 8 (19.0) 34 (81.0)
Indian 81 (29.2) 35 (43.2) 9 (25.7) 26 (74.3)
Chinese 59 (21.3) 32 (54.2) 12 (37.5) 20 (62.5)
Bumiputera/Orang Asli 44 (15.9) 31 (70.5) 13 (41.9) 18 (58.1) 0.129
Other 0 (0.0) 0 n/a 0 n/a 0 n/a
1Individuals aged seven years or above and covered in the most recent HDSS enumeration, who had not moved away or passed away since the most recent enumeration.
2Eligible individuals who were available to respond to an invitation to participate in the study at the time of visit.
Differences in distributions across categories of response were compared using Pearson’s chi squared or Fisher’s exact (cell counts < 5) tests.
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Table 2. Detailed summary of data and sample collection completeness, stratified by sex.
n (%)
Adults Children
Overall Men Women Overall Boys Girls
N 161 59 102 42 23 19
Questionnaire data
Any questionnaire data
post-cleaning
161 (100.0) 59 (100.0) 102 (100.0) 42 (100.0) 23 (100.0) 19 (100.0)
Complete questionnaire
data post-cleaning
13 (8.1) 6 (10.2) 7 (6.9) 12 (28.6) 8 (34.8) 4 (21.1)
Samples for point-of-care analysis
Capillary (finger-prick)
blood sample
successfully obtained
161 (100.0) 59 (100.0) 102 (100.0) 42 (100.0) 23 (100.0) 19 (100.0)
Samples for analysis and storage collected at full volume
Any venous blood
sample1
143 (88.8) 57 (96.6) 86 (84.3) 41 (97.6) 23 (100.0) 18 (94.7)
All venous blood
samples2
111 (68.9) 43 (72.9) 68 (66.7) 38 (90.5) 22 (95.7) 16 (84.2)
Any venous blood
sample1 or hair sample
or urine sample
161 (100.0) 59 (100.0) 102 (100.0)
Any venous blood
sample1 and hair sample
and urine sample
115 (71.4) 34 (57.6) 81 (79.4)
All venous blood
samples2 and hair
sample and urine
sample
91 (56.5) 26 (44.1) 65 (63.7)
Venous blood samples for analysis and storage collected at full volume
Plain serum blood
sample
141 (87.6) 57 (96.6) 84 (82.4) 39 (92.9) 22 (95.7) 17 (89.5)
EDTA (plasma) blood
sample
139 (86.3) 55 (93.2) 84 (82.4) 41 (97.6) 23 (100.0) 18 (94.7)
EDTA (whole blood 1)
blood sample
131 (81.4) 52 (88.1) 79 (77.5) 40 (95.2) 23 (100.0) 17 (89.5)
EDTA (whole blood 2)
blood sample
115 (71.4) 48 (81.4) 69 (67.6) 40 (95.2) 23 (100.0) 17 (89.5)
Hair and urine samples collected
Hair sample 134 (83.2) 35 (59.3) 99 (97.1)
Urine sample (full
volume)
157 (97.5) 59 (100.0) 98 (96.1)
Blood analysis data
Any blood test data 148 (91.9) 58 (98.3) 90 (88.2) 41 (97.6) 23 (100.0) 18 (94.7)
Complete blood test
data
125 (77.6) 53 (89.8) 72 (70.6) 29 (69.0) 16 (69.6) 13 (68.4)
EDTA: ethylene diamine tetra-acetic acid.
1At least one of: plain serum or EDTA (plasma) or EDTA (whole blood 1) or EDTA (whole blood 2).
2All of: plain serum and EDTA (plasma) and EDTA (whole blood 1) and EDTA (whole blood 2).
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planning similar data and sample collections in other low- and
middle-income populations.
While most outcomes assessed here indicated successful estab-
lishment of study operations, we identified two areas requiring
improvement, which may be successfully addressed through sim-
ple modifications to study design and training. This included the
slow study pace relative to the number of field teams and time
taken per session of data and sample collection. This survey
design-related issue was likely a result of the notable proportion
of houses empty upon approach, due to outmigration or unavail-
ability of household members at the time of recruitment. This,
along with the predominantly rural setting and large sampling
area, increased the travel time between houses with consenting
individuals. More suitable methods of recruitment to improve
study efficiency could include approaching sampled households
in a separate recruitment drive to establish availability, willingness
to participate, and to arrange convenient time windows for data
and sample collection. We also observed lower blood sample col-
lection success among obese participants, an issue specific to bio-
marker collection which may be resolved by further directed
training of study phlebotomists.
The proportion of participating individuals in this study, along
with differential response to participation across demographic
subgroups, may suggest implications for generalisability.
Although the demographic profile of this study may not be
fully representative of the wider population, analyses arising
from this study have the capacity to produce internally valid
results regarding aetiological relationships, with wider relevance
to other populations (11). Nonetheless, our observations indicate
an opportunity to further improve recruitment strategies overall
and across specific subgroups, in future data and sample
collections.
The high burden of cardiometabolic risk factors observed in
the current study population is consistent with previous findings
from the SEACO HDSS (26, 27). Similar trends have been
reported in other middle-income countries including those
from Asia, and are thought to be a result of epidemiologic transi-
tions occurring in these populations (28–31). These observations
reinforce the need for large-scale biomarker data from such popu-
lations to comprehensively assess disease risk and associated
influences across the life course. We demonstrate here that exist-
ing HDSS resources can be successfully augmented to achieve this
purpose.
We present a study undertaken within a specific context, with
basic infrastructure and resources already in place through the
SEACO HDSS and augmented by collaborating institutions.
Given our context and particular interests, we made specific
choices regarding study design, including biological samples of
interest, consent structure, the collection of non-fasting blood
samples, and test result feedback and onward referral of partici-
pants. Researchers planning biomarker collections in other set-
tings must consider their specific contexts and aims to inform
decisions relating to suitable study design. Importantly, the mea-
sures presented here may be applicable and useful to understand-
ing the feasibility of such biomarker collections regardless of exact
study methodology.
To conclude, we show that biological sample collections to cre-
ate biodata resources using existing HDSS frameworks are feas-
ible. Using this approach, we identify a potentially high burden
of cardiometabolic risk factors that requires further evaluation
in this population. Building upon existing HDSS resources in
this way would greatly enhance their scientific value, and contrib-
ute towards addressing the need for comprehensive biomarker
data from low- and middle-income populations.
Table 3. Summary of venous blood sample collection completeness and quality from adults and children.
n (%)
Any volume Full volume
Any volume +
accepted by
laboratory
Full volume +
accepted by
laboratory
Adults (N = 161)
Plain serum blood sample 148 (91.9) 141 (87.6) 145 (90.1) 141 (87.6)
EDTA (plasma) blood sample 142 (88.2) 139 (86.3) 142 (88.2) 139 (86.3)
EDTA (whole blood 1) blood sample 141 (87.6) 131 (81.4) 139 (86.3) 131 (81.4)
EDTA (whole blood 2) blood sample 133 (82.6) 115 (71.4) 132 (82.0) 115 (71.4)
At least one blood sample 148 (91.9) 143 (88.8) 145 (90.1) 143 (88.8)
All blood samples 133 (82.6) 111 (68.9) 132 (82.0) 111 (68.9)
Children (N = 42)
Plain serum blood sample 41 (97.6) 39 (92.9) 40 (95.2) 39 (92.9)
EDTA (plasma) blood sample 41 (97.6) 41 (97.6) 41 (97.6) 41 (97.6)
EDTA (whole blood 1) blood sample 40 (95.2) 40 (95.2) 40 (95.2) 40 (95.2)
EDTA (whole blood 2) blood sample 40 (95.2) 40 (95.2) 40 (95.2) 40 (95.2)
At least one blood sample 41 (97.6) 41 (97.6) 41 (97.6) 41 (97.6)
All blood samples 40 (95.2) 38 (90.5) 39 (92.9) 38 (90.5)
EDTA: ethylene diamine tetra-acetic acid.
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Table 4. Crude prevalence of selected lifestyle, biophysical and blood-based risk factors in the study population.
Number and crude prevalence (n, %)
Overall Men Women P Overall Boys Girls P
N 161 59 (36.7) 102 (63.4) 42 23 (54.8) 19 (45.2)
Current smoker 24 (14.9) 22 (37.3) 2 (2.0) <0.001 2 (4.8) 2 (8.7) 0 (0.0) 0.492
Any alcohol consumption in past 12 months 20 (12.4) 14 (23.7) 6 (5.9) 0.001 1 (2.4) 1 (4.4) 0 (0.0) 1.000
Low fruit and vegetable consumption 157 (98.1) 59 (100.0) 98 (97.0) 0.297 38 (92.7) 22 (95.7) 16 (88.9) 0.573
Insufficient physical activity 63 (39.1) 18 (30.5) 45 (44.1) 0.088
Overweight 97 (60.6) 32 (54.2) 65 (64.4) 0.206 10 (23.8) 5 (21.7) 5 (26.3) 0.729
Obesity 39 (24.4) 10 (17.0) 29 (28.7) 0.095 3 (7.1) 0 (0.0) 3 (15.8) 0.084
Underweight 5 (11.9) 5 (21.7) 0 (0.0) 0.053
Stunting 3 (7.1) 2 (8.7) 1 (5.3) 0.573
Central obesity 100 (62.5) 26 (44.1) 74 (73.3) <0.001 1 (2.4) 0 (0.0) 1 (5.3) 0.452
Elevated waist to hip ratio 84 (52.5) 34 (57.6) 50 (49.5) 0.321
Hypertension1 71 (44.1) 30 (50.9) 41 (40.2) 0.190 6 (14.3) 5 (21.7) 1 (5.3) 0.197
Elevated HbA1c2 38 (23.8) 8 (13.6) 30 (29.7) 0.021 0 (0.0) 0 (0.0) 0 (0.0)
Anaemia 26 (16.2) 0 (0.0) 26 (25.5) <0.001 4 (9.5) 0 (0.0) 4 (21.1) 0.035
Elevated total cholesterol1 12 (8.2) 5 (8.6) 7 (7.9) 0.870 8 (19.5) 2 (8.7) 6 (33.3) 0.109
Low HDL cholesterol 22 (15.0) 11 (19.0) 11 (12.4) 0.345 6 (14.6) 4 (17.4) 2 (11.1) 0.679
Elevated triglycerides 56 (38.1) 26 (44.8) 30 (33.7) 0.175 15 (36.6) 9 (39.1) 6 (33.3) 0.702
HbA1c: glycated haemoglobin. HDL: high-density lipoprotein.
Classification of all risk factors is described in the Supplementary Methods.
Differences in distributions between men and women or boys and girls were assessed using Pearson’s chi squared or Fisher’s exact (cell counts < 5) test.
N was reduced due to missing observations for the following measures: (1) Low fruit and vegetable consumption among girls (N = 18); (2) Overweight, obesity, central obesity and elevated waist to hip ratio and elevated HbA1c among women (N = 101);
(3) Elevated HbA1c in girls (N = 18); (4) All cholesterol and triglyceride measures among girls (N = 18), men (N = 58) and women (N = 89).
1Measures for hypertension and elevated cholesterol prevalence included individuals who reported being told they had elevated blood pressure or cholesterol.
2HbA1c as measured at the point of care.
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Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/gheg.2018.13.
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